Get started
Author

Nobuhide Izumi

A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results
2016 · M. Buti, E. Gane, et al. · Journal of Hepatology · 17
A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
2017 · M. Brunetto, Y.S. Lim, et al. · Journal of Hepatology · 14
Platelet life span in uraemia.
1985 · H Tanaka, K Umimoto, et al. · PubMed · 6
P933 Once-daily Oral Lusutrombopag, Alternative to Platelet Transfusion in Thrombocytopenic Patients With Chronic Liver Disease Undergoing Radiofrequency Ablation: Results From a Phase 2b, Randomized, Double-blind Study
2014 · N. Izumi, R. Tateishi, et al. · Journal of Hepatology · 5
Platelet dysfunction and its life span in uremia.
1984 · H Tanaka, K Uminoto, et al. · PubMed · 5
Fluorescein angiography in patients undergoing hemodialysis.
1993 · Masaru Umeda, Hiroyuki Iwata, et al. · Journal of Japanese Society for Dialysis Therapy · 3
PDF
Fatigue and associated factors in maintenance hemodialysis patients
2019 · Noriko Nakahara, Kazumi Nishiguchi, et al. · Nihon Toseki Igakkai Zasshi · 2
PDF
1169 Genetic Polymorphism in Il28b Predicts Null Virological Response to Pegylated-interferon Plus Ribavirin Therapy for Chronic Hepatitis C
2010 · M. Kurosaki, Y. Tanaka, et al. · Journal of Hepatology · 2
1178 Genome-wide Association Study Identifies Il28b Associated With Response to Pegylated Interferon-alfa and Ribavirin Therapy for Japanese Patients With Chronic Hepatitis C
2010 · Y. Tanaka, N. Nishida, et al. · Journal of Hepatology · 2
Red Blood Cell Aluminum in Patients with Renal Failure and Effect of Desferrioxamine Infusion
2008 · M. Umeda, K. Tsurusaki, et al. · Blood Purification · 2
Evaluation of interferon .BETA. treatment for chronic hepatitis C in a hemodialysis patient.
1994 · Masaru Umeda, Hidetoshi Minami, et al. · Nihon Toseki Igakkai Zasshi · 2
PDF
Improvement of carbohydrate metabolism by hemofiltration.
1981 · Sakae Yamagami, Mikio Ohta, et al. · 人工臓器 · 2
499 Very-early Viral Response (week-1) to Triple Therapy With Telaprevir, Peg-interferon and Ribavirin Predicts Extended-rvr and Treatment Outcomes in Patients With Hcv Genotype 1
2013 · K. Takaguchi, H. Toyota, et al. · Journal of Hepatology · 1
PDF
582 High response rates with peginter-feron α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in Japanese non-responders or relapsers to conventional interferon
2006 · N. Izumi, S. Iino, et al. · Journal of Hepatology · 1
PDF
Pharmacokinetics of levofloxacin in hemodialyzed patients.
1997 · Masaru Umeda, Nobuhide Izumi, et al. · Nihon Toseki Igakkai Zasshi · 1
PDF
Study of the clearance of new quinolone agents in patients undergoing hemodialysis.
1993 · Masaru Umeda, Hidetoshi Minami, et al. · Journal of Japanese Society for Dialysis Therapy · 1
PDF
Effect of desferrioxamine infusion on red blood cell aluminum.
1988 · M Umeda, K Umimoto, et al. · PubMed · 1
Can hemodialysis remove the factor that suppresses platelet cyclo-oxygenase activity in uremic patients?
1985 · H Tanaka, K Umimoto, et al. · PubMed · 1
SY5-4 New treatment strategy for intermediate-stage hepatocellular carcinoma: combination of local and systemic therapy
2024 · K. Tsuchiya, Y. Yasui, et al. · Annals of Oncology
PDF
Pf698 Lusutrombopag Reliably Increases Platelets Regardless of Baseline Platelet Counts in Thrombocytopenic Chronic Liver Disease Patients Undergoing Planned Invasive Procedures: Results of 2 Phase 3 Trials
2019 · R.S. Brown, M. Imawari, et al. · HemaSphere
Hepatitis B surface antigen reduction by switching from long-term preceding nucleoside/nucleotide analog administration to pegylated interferon or tenofovir
2018 · T. Nobuharu, M. Kurosaki, et al. · Journal of Hepatology
Real world experience of lusutrombopag for thrombocytopenia in patients with liver cirrhosis
2018 · H. Takada, N. Izumi, et al. · Journal of Hepatology
Use of noninvasive biomarkers to assess fibrosis regression in cirrhotic patients during nucleos(t)ide therapy
2018 · C. Pan, N. Izumi, et al. · Journal of Hepatology
Serum hepatocyte growth factor (HGF) is a potential marker for baseline liver function and its early deterioration in patients treated with sorafenib
2017 · Y. Yasui, M. Kurosaki, et al. · Journal of Hepatology
P553 Elastic Fiber Accumulation Estimated by a Novel Automated Computational Analysis as a Significant Predicting Factor for the Development of Hepatocellular Carcinoma
2014 · Y. Yasui, T. Abe, et al. · Journal of Hepatology
Works count: 37
Citation count: 68
H-index: 5
I10-index: 2
Year
Topic
Type